Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michael Stein

Showing results (11-20 of 263) with videos related to

Pageof 27
Sort By:
The Journal of Rheumatology|March 5, 2025
Drs. Stein and Ormseth replyC Michael Stein, Michelle J Ormseth
Current Opinion in Lipidology|December 29, 2015
High-density lipoprotein function in rheumatoid arthritisMichelle J Ormseth, C Michael Stein
Clinical Pharmacology and Therapeutics|October 10, 2003
The Gly389Arg beta1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?Otto-Erich Brodde, C Michael Stein
The New England Journal of Medicine|January 13, 2006
Reform of drug regulation--beyond an independent drug-safety boardWayne A Ray, C Michael Stein
The New England Journal of Medicine|May 21, 2004
New drugs for rheumatoid arthritisNancy J Olsen, C Michael Stein
The New England Journal of Medicine|October 1, 2010
The ethics of placebo in studies with fracture end points in osteoporosisC Michael Stein, Wayne A Ray
The Journal of Rheumatology|October 3, 2014
Is visceral fat the missing link in the relationship between inflammation and insulin resistance in RA?Michelle J Ormseth, C Michael Stein
Circulation|April 29, 2009
Clopidogrel and the concept of high-risk pharmacokineticsDan M Roden, C Michael Stein
Clinical Pharmacology and Therapeutics|July 4, 2006
Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulantsUte I Schwarz, C Michael Stein
Annals of Internal Medicine|January 5, 2002
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?Theodore Pincus, Tuulikki Sokka, C Michael Stein
Pageof 27

Showing results (11-20 of 263) with videos related to

Sort By:
Pageof 27
The Journal of Rheumatology|March 5, 2025
Drs. Stein and Ormseth replyC Michael Stein, Michelle J Ormseth
Current Opinion in Lipidology|December 29, 2015
High-density lipoprotein function in rheumatoid arthritisMichelle J Ormseth, C Michael Stein
Clinical Pharmacology and Therapeutics|October 10, 2003
The Gly389Arg beta1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment?Otto-Erich Brodde, C Michael Stein
The New England Journal of Medicine|January 13, 2006
Reform of drug regulation--beyond an independent drug-safety boardWayne A Ray, C Michael Stein
The New England Journal of Medicine|May 21, 2004
New drugs for rheumatoid arthritisNancy J Olsen, C Michael Stein
The New England Journal of Medicine|October 1, 2010
The ethics of placebo in studies with fracture end points in osteoporosisC Michael Stein, Wayne A Ray
The Journal of Rheumatology|October 3, 2014
Is visceral fat the missing link in the relationship between inflammation and insulin resistance in RA?Michelle J Ormseth, C Michael Stein
Circulation|April 29, 2009
Clopidogrel and the concept of high-risk pharmacokineticsDan M Roden, C Michael Stein
Clinical Pharmacology and Therapeutics|July 4, 2006
Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulantsUte I Schwarz, C Michael Stein
Annals of Internal Medicine|January 5, 2002
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?Theodore Pincus, Tuulikki Sokka, C Michael Stein
Pageof 27